Lindenwold Advisors’s ResMed RMD Stock Holding History

Lindenwold Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.3M	Buy	8,403 +158	+2%	+$43.2K	1.09%	28
2025 Q2	$2.13M	Buy	+8,245	New	+$1.97M	1.1%	27

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Lindenwold Advisors's RMD Position: Q3 2025 in Review

Lindenwold Advisors increased its ResMed (RMD) stake by 1.9% in Q3 2025, buying an estimated $43.2K and bringing the position to 8,403 shares worth $2.3M. The position accounts for 1.09% of the portfolio, ranked #28.

Lindenwold Advisors first reported a position in RMD in Q2 2025 and has held it in 2 quarters since. 950 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

Lindenwold Advisors held 8,403 shares of ResMed worth $2.3M as of Q3 2025.
Lindenwold Advisors bought 158 ResMed shares in Q3 2025, an estimated $43.2K.
ResMed made up 1.09% of Lindenwold Advisors's portfolio in Q3 2025, its #28 holding.
Lindenwold Advisors first reported a position in ResMed in Q2 2025 and has held it in 2 quarters since.
950 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Lindenwold Advisors's 13F filing for Q3 2025, filed 16 Dec 2025.